EGFR and metastatic neoplasm: Anti-EGFR therapies have increased response rates and conversion from unresectable to resectable metastatic disease when added to chemotherapy with FOLFOX or FOLFIRI for patients with RAS wild type,46,47 but more recent data suggest that benefit with anti-EGFR therapies seems to be limited to patients whose primary tumors are left sided.10,12,18,20 This is discussed in the cost-effectiveness literature48-50; however, some of this literature indicates limited cost effectiveness.